Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Potential role of sorafenib in the treatment of acute myeloid leukemia. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
The roles of FLT3 in hematopoiesis and leukemia. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16 16)(p13 q22): results from CALGB 8461. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Patients with t(8 21)(q22 q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cytarabine dose for acute myeloid leukemia. This study showed a survival benefit with higher dose daunorubicin in younger patients Anthracycline dose intensification in acute myeloid leukemia. High-dose daunorubicin in older patients with acute myeloid leukemia. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.
Yates JW, Wallace Jr HJ, Ellison RR, Holland JF. Papers of particular interest, published recently, have been highlighted as:
0 kommentar(er)
